Adalat and Inflectra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Adalat (nifedipine) and Inflectra (infliximab-dyyb). Common drug interactions include muscular weakness among females and chest discomfort among males.

The phase IV clinical study analyzes what interactions people have when they take Adalat and Inflectra. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Adalat?

Adalat has active ingredients of nifedipine. It is often used in high blood pressure. eHealthMe is studying from 20,940 Adalat users. Check the latest studies of Adalat.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

On Aug, 01, 2026

49 people who take Adalat and Inflectra together, and have interactions are studied.

What are the common drug interactions of Adalat and Inflectra, by gender? *:

female:

Muscular weakness (muscle weakness)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Tremor (trembling or shaking movements in one or more parts of your body)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Arthralgia (joint pain)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Drug ineffective
Joint swelling
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Thyroidectomy

male:

Chest discomfort
Chest pain
Peripheral embolism (sudden interruption of blood flow to an organ or body part)
Pruritus (severe itching of the skin)
Pulmonary embolism (blockage of the main artery of the lung)
Rash
Somnolence (a state of near-sleep, a strong desire for sleep)
Thrombosis (formation of a blood clot inside a blood vessel)
Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
Drug hypersensitivity

What are the common drug interactions of Adalat and Inflectra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Muscular weakness (muscle weakness)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Livedo reticularis (a lace-like purplish discoloration of the skin)
Muscle spasms (muscle contraction)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Peripheral coldness
Peripheral embolism (sudden interruption of blood flow to an organ or body part)
Pruritus (severe itching of the skin)
Pulmonary embolism (blockage of the main artery of the lung)
Rash

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 16 people, 32.65%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 11 people, 22.45%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 16.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 14.29%
Takayasu's Arteritis (an inflammation of the aorta -- the artery that carries blood from the heart to the rest of the body): 4 people, 8.16%

* Approximation only. Some reports may have incomplete information.

Do you take Adalat and Inflectra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously